133 related articles for article (PubMed ID: 9582297)
1. Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.
Capranico G; Guano F; Moro S; Zagotto G; Sissi C; Gatto B; Zunino F; Menta E; Palumbo M
J Biol Chem; 1998 May; 273(21):12732-9. PubMed ID: 9582297
[TBL] [Abstract][Full Text] [Related]
2. DNA-binding preferences of bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning.
Sissi C; Bolgan L; Moro S; Zagotto G; Bailly C; Menta E; Capranico G; Palumbo M
Mol Pharmacol; 1998 Dec; 54(6):1036-45. PubMed ID: 9855632
[TBL] [Abstract][Full Text] [Related]
3. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
Zagotto G; Oliva A; Guano F; Menta E; Capranico G; Palumbo M
Bioorg Med Chem Lett; 1998 Jan; 8(2):121-6. PubMed ID: 9871638
[TBL] [Abstract][Full Text] [Related]
5. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy.
Chourpa I; Morjani H; Riou JF; Manfait M
FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
[TBL] [Abstract][Full Text] [Related]
8. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
10. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
11. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.
Ketron AC; Denny WA; Graves DE; Osheroff N
Biochemistry; 2012 Feb; 51(8):1730-9. PubMed ID: 22304499
[TBL] [Abstract][Full Text] [Related]
12. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
14. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
16. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
Pommier Y; Capranico G; Orr A; Kohn KW
Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
[TBL] [Abstract][Full Text] [Related]
17. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Baguley BC; Holdaway KM; Fray LM
J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
[TBL] [Abstract][Full Text] [Related]
18. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
19. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Robinson MJ; Osheroff N
Biochemistry; 1990 Mar; 29(10):2511-5. PubMed ID: 2159323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]